GHK-Cu on skin and in a shot raise different questions.

What the name describes

GHK is a chain of three protein-building parts, and GHK-Cu is that chain joined to copper.

Copper tripeptide-1 is another name used for this ingredient in skin products.

What has, and has not, been approved

Whatever the use or form, no GHK-Cu medicine had approval from FDA (the US Food and Drug Administration) as of September 30, 2026.

A naming entry in a government register does not give a product approval.

The compounding entries are different

As of September 30, 2026, non-injected GHK-Cu was in FDA’s category 1: ingredients still being evaluated for use in pharmacy-made medicines. FDA says it does not plan to act to stop makers from compounding with these ingredients if they meet its temporary policy’s conditions.

Being in category 1 does not mean the medicine has FDA approval or that a particular preparation is lawful.

Ask the preparing pharmacy to identify the policy conditions for this ingredient and explain how its preparation meets them. Also ask which prescription and quality rules apply. The category name alone cannot settle whether your offer is lawful.

On FDA’s page marked current to April 22, 2026, injected GHK-Cu appears among ingredients whose requests for consideration for compounding were withdrawn. FDA still lists concerns about a reaction by the body’s defences and limited safety information in people.

The request to have FDA consider the ingredient for compounding was taken back. That withdrawal does not mean FDA cleared it for use.

Choose the open question to follow